Up a level |
Journal Article
Bosse, Autoren K., Faust, U., Gruber, I, Habhab, W., Guenther, G., Siebers-Renelt, U., Kiechle, M., Speiser, D., Dikow, N., Kast, K., Arnold, N., Vesper, A-S, Harbeck, N., Briest, S., Thomssen, C., Gehrig, A., Wallaschek, H., Solbach, C., Wolf, M., Witzel, I, Holzhauser, I, Kaulfuss, S., Janni, W., Engel, C., Riess, O., Schmutzler, R. and Schroeder, C. (2020). Clinical-pathological Characterization of 1078 Advice Seekers with pathogenic CHEK2 Mutation from the German Consortium of Familial Breast and Ovarian Cancer (DK-FBREK). Geburtshilfe Frauenheilkd., 80 (6). S. E23 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Habhab, W., Faust, U., Guenther, G., Siebers-Renelt, U., Kiechle, M., Ott, C., Dikow, N., Kast, K., Vesper, A., Solbach, C., Harbeck, N., Stiller, M., Gehrig, A., Thomssen, C., Wallaschek, H., Arnold, N., Holzhauser, I., Kaulfuss, S., Volk, A., Janni, W., Engel, C., Schmutzler, R., Riess, O., Schroeder, C. and Bosse, K. (2020). Clinical and molecular characterization of 1253 carriers of a deleterious CHEK2 mutation from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Eur. J. Hum. Genet., 28 (SUPPL 1). S. 93 - 95. LONDON: SPRINGERNATURE. ISSN 1476-5438
Huober, J., Janni, W., Untch, M., Blohmer, J-U., Zahm, D-M., Hanusch, C., Jackisch, C., Heinrich, G., Schneeweiss, A., Denkert, C., Link, T., Rhiem, K. E., Furlanetto, J., Solbach, C., Klare, P., Nekljudova, V., Filmann, N. and Loibl, S. (2022). Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Ann. Oncol., 33 (7). S. S615 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Labidi-Galy, S. I., Schneeweiss, A., Sinn, H. P., Blohmer, J-U., Romanens, L., Zahm, D-M., Huober, J., Dohnal, D., Link, T., Hanusch, C., Jackisch, C., Fasching, P. A., Solbach, C., Rhiem, K. E., Denkert, C., Weber, K. E., Lederer, B., Untch, M., Loibl, S. and Furlanetto, J. (2021). Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto. Ann. Oncol., 32. S. S49 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Reinisch, M., Denkert, C., Fasching, P. A., Seiler, S., Link, T., Hanusch, C., Bjelic-Radisic, V., Schneeweiss, A., Huober, J., Jackisch, C., Rhiem, K. E., Untch, M., Solbach, C., Blohmer, J-U., Buechele, T., Nekljudova, V. and Loi, S. (2022). A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)-GeparPiPPa. Ann. Oncol., 33 (7). S. S627 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J. U., Furlanetto, J., Zahm, D. M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P. A., Nekljudova, V., Denkert, C. and Untch, M. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann. Oncol., 33 (11). S. 1149 - 1159. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M., Blohmer, J-U., Jackisch, C., Reinisch, M., Rhiem, K. E., Schneeweiss, A., Solbach, C., Schoellhorn, L., Fasching, P. A., Rey, J. and Loibl, S. (2021). Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. Ann. Oncol., 32. S. S443 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V. and Loibl, S. (2022). Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). Ann. Oncol., 33. S. S166 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Rhiem, K., Bick, U., Kast, K., Niederacher, D., Solbach, C., Emons, G., Witzel, I., Brigitte, S., Bartram, C., Maass, N., Lemke, J., Kiechle, M., Mahner, S., Wieacker, P., Ortmann, O., Riess, O., Janni, W., Haaf, T. and Schmutzler, R. K. (2018). New structures of the German Consortium for Hereditary Breast and Ovarian Cancer. Oncol. Res. Treat., 41. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262
Schneeweiss, A., Moebus, V., Tesch, H., Klare, P., Denkert, C., Kast, K., Hanusch, C., Link, T., Untch, M., Jackisch, C., Blohmer, J-U., Fasching, P. A., Solbach, C., Huober, J., Rhiem, K. E., Nekljudova, V., Luebbe, K. and Loibl, S. (2020). Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC). Ann. Oncol., 31. S. S303 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041